InsiderDB
Sign inStart free trial

Sen. Ron Wyden sold Solventum (SOLV)

Sen. Ron Wyden (D-OR) · $1K–$15K · traded Feb 6, 2025

Transaction
Sold (full)
Amount
$1K–$15K
Owner
Spouse
Traded
Feb 6, 2025
Disclosed
Feb 21, 2025
Days to disclose
15
Asset type
Stock
As filed
Solventum Corporation
Industry
Medical - Instruments & Supplies · Healthcare
Official filing ↗All of Wyden's tradesAll Congress trades in SOLV

Other trades in this filing

  • Sold (full) Eli Lilly and Company LLY

    $50K–$100K · Traded Feb 10, 2025 · disclosed Feb 21, 2025 · Spouse

    Committee overlap: FinanceGot $20K from the company’s PAC

  • Sold (full) iRobot IRBT

    $1K–$15K · Traded Feb 6, 2025 · disclosed Feb 21, 2025 · Spouse

  • Bought Eli Lilly and Company LLY

    $50K–$100K · Traded Jan 22, 2025 · disclosed Feb 21, 2025 · Spouse

    Committee overlap: FinanceGot $20K from the company’s PAC

Recent Congress trades in SOLV

Company context for SOLV

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. SOLVLobbying report·Lobbying disclosures

    SOLV: third_quarter 2026 lobbying report

    -Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and

    Public: Oct 20, 2026, 10:48 PM EDTOriginal source ↗
  2. SOLVLobbying report·Lobbying disclosures

    SOLV: third_quarter 2026 lobbying report

    Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development. Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.

    Public: Oct 19, 2026, 7:42 PM EDTOriginal source ↗
  3. SOLVLobbying report·Lobbying disclosures

    SOLV: second_quarter 2026 lobbying report

    -Issues related to Department of Defense policy, procurement, and contracting processes for medical technology. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to domestic and global medical supply chain resilience. -Tariff issues generally. -Issues related to the 232 investigation of imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices. -Issues related to Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure to Impose and Effectively Enforce a Prohibition on

    Public: Jul 20, 2026, 9:15 PM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.